Markets
PTE

PolarityTE Reports Positive Data From Interim Analysis Of SkinTE Diabetic Foot Ulcer Trial

(RTTNews) - PolarityTE Inc. (PTE) announced positive results from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE plus standard of care or SOC vs SOC alone.

The company stated that 50 patients were evaluated across 13 sites with 25 patients receiving SkinTE plus SOC and 25 patients receiving only SOC.

The company stated that demographics were well balanced between treatment groups with no statistically significant differences.

The company noted that all SkinTE patients received only one application of the product, except two patients who received a reapplication due to inadvertent removal of the original product.

PolarityTE said that 72% of patients treated with SkinTE plus SOC achieved wound closure by 12 weeks vs 32% of patients treated with SOC alone.

According to the company, preliminary analysis showed that SkinTE treatment did not result in more Adverse Events (AEs) than SOC.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PTE

Latest Markets Videos

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More